Compare Monster Beverage Corp (MNST) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Neurocrine Biosciences Inc — how do they compare? Monster Beverage Corp trades at $93.91 (market cap $93.35B), while Neurocrine Biosciences Inc trades at $179 (market cap $17.40B). The key difference: Monster Beverage Corp is far larger — about 5.4× Neurocrine Biosciences Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Monster Beverage Corp nearer its low. Which is the better fit depends on your goals.
| MNST | NBIX | |
|---|---|---|
Market Cap | $93.35B | $17.40B |
Sector | Consumer Staples | Health |
52-Week High | $99.94 | $180.55 |
52-Week Low | $58.75 | $123.10 |
Enterprise Value | $91.65B | $16.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $94.46, down 3.12% on the day, with a bullish technical outlook supported by moving averages and ADX signals. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.58 exceeding the $0.527 estimate, and maintains robust profitability with a net income margin of 23.11%. A 2-for-1 stock split is scheduled for August 2026, reflecting confidence in future growth.
The investment outlook is positive, driven by consistent earnings outperformance, international expansion, and product innovation. Risks include elevated valuation multiples (P/E of 46.11) and competitive pressures in the beverage sector. Analyst consensus is bullish with a $97.83 price target, suggesting modest upside from current levels.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
